Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
BioNTech SE
AbbVie
Bristol-Myers Squibb
AbbVie
Second Affiliated Hospital of Nanchang University
Rigshospitalet, Denmark
Cancer Research UK
Hansoh BioMedical R&D Company
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Hunan Province Tumor Hospital
Chang Gung Memorial Hospital